BioLineRx to Report Second Quarter 2026 Results on August 31, 2026
BioLineRx (NASDAQ: BLRX) announced it will release unaudited financial results for the second quarter ended June 30, 2026, on Monday, August 31, 2026, before U.S. markets open.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioLineRx (NASDAQ: BLRX) announced it will release unaudited financial results for the second quarter ended June 30, 2026, on Monday, August 31, 2026, before U.S. markets open. Management will host a conference call at 8:30 a.m. EDT, featuring remarks by CEO Philip Serlin.
Investors can join the call by dialing +1-888-407-2553 from the U.S. or +972-3-918-0685 internationally. A live webcast and replay will be available via the event page on the company’s website. A dial-in replay will be accessible until September 1, 2026, at +1-888-295-2634 (U.S.) or +972-3-925-5904 (international).
Details
Market move: BLRX -5.00% in the Aug 25 session. 2Q26 earnings report
On Aug 25, the day this news came out, BLRX closed 5.00% below the previous close.
Data tracked by StockTitan Argus for the Aug 25 session.
Key Figures
- Results period
- Second quarter 2026
- Unaudited financial results
- Reporting period end
- June 30, 2026
- Second quarter 2026
- Release date
- August 31, 2026
- Before U.S. markets open
- Conference call time
- 8:30 a.m. EDT
- August 31, 2026
Previous Earnings date Reports
-
Announced Q1 2026 results release date and management conference call
-
Announced 2025 annual results release date and management conference call
-
Announced third-quarter 2025 results release date and conference call
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Management to Hold Conference Call at 8:30 a.m. EDT
The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer.
To access the conference call, please dial +1-888-407-2553 from the
About BioLineRx
BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's lead development asset is GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial has been initiated in the first quarter of 2026. GLIX1 is being developed under a collaboration with Hemispherian AS.
The Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop motixafortide in solid tumors, including metastatic pancreatic cancer (PDAC), and has a Phase 2b PDAC trial currently ongoing under a collaboration with Columbia University.
Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on LinkedIn.
CONTACTS:
United States
Chuck Padala
LifeSci Advisors, LLC
IR@biolinerx.com
Israel
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolinerx-to-report-second-quarter-2026-results-on-august-31-2026-302859223.html
SOURCE BioLineRx Ltd.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.